Title:The Use of Daflon Tablets in Treating Hemorrhoids and Alleviating
Symptoms
Volume: 19
Issue: 5
Author(s): Leila Hajimaghsoudi, Mojtaba Ahmadinejad, Mohsen Karimian, Mohammad Hadi Bahri, Ali Karbalaeikhani and Izadmehr Ahmadinejad*
Affiliation:
- Department of
Medicine, Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
Keywords:
Daflon, hemorrhoid, dentate line, varicose, prolapse, anus.
Abstract:
Background: Varicose-like bulging veins that occur in the anus and lower rectum are
known as hemorrhoids. Depending on their degree of prolapse, they can cause symptoms such as
bleeding, discomfort, mucous discharge, perianal irritation, and burning. The aim of the study was
to investigate the impact of Daflon pills on the treatment of hemorrhoids and their associated symptoms,
as well as the duration of hospitalization and the likelihood of recurrence.
Methods: A randomized clinical trial was used in this investigation. Patients who had been referred
to the surgical clinic of the Madani Hospital in 2021 with hemorrhoid complaints were participants
in a random selection process. Participants were separated into control groups (getting non-invasive
regular treatments) and the intervention group after being informed and given ethical approval (Receiving
Daflon 500 mg twice daily for 4 weeks). Patients' symptoms, potential sequelae, and illness
recurrence were assessed in both chosen groups at each visit, and data was gathered until the desired
sample size was reached.
Results: This study was performed on 200 patients who received Daflon 500 mg (intervention, N =
100) or placebo (control, N = 100). The number of visits required to achieve therapeutic goals did
not differ statistically significantly between the intervention and control groups (P > 0.05). The
mean recovery time was 56.5 ± 12.53 days for the intervention group and 61.04 ± 13.63 days for the
control group, which is considered statistically significant (P < 0.05). A total of 56 patients (28.0%)
relapsed and 144 patients (72.0%) recovered. This rate in the intervention group included 78
(78.0%) recovery and 22 (22.0%) relapsed and in the control group 66 (66.0%) recovered and 34
(34.0%) relapsed, clinically it suggests that treatment Daflon can prevent relapse of the disease, although
the statistical results of this study do not support this hypothesis (P = 0.059).
Conclusion: The study's findings demonstrated that Daflon therapy is a superior and more effective
treatment option for all grades of hemorrhoids. Moreover, the medication's side effects are manageable,
making it a well-tolerated choice.
